This clinical trial is focused on studying the effects of a medication called XEN1101 on individuals with focal onset seizures. Focal onset seizures are a type of epilepsy where seizures start in one area of the brain. The medication being tested, XEN1101, is taken in the form of a capsule and is being compared to a placebo to see how well it works in reducing the frequency of these seizures. The main goal of the study is to assess the effect of XEN1101 on reducing the number of seizures experienced by participants.

Participants in the study will be randomly assigned to receive either XEN1101 or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The study will last for a period of 12 weeks, during which participants will take the medication or placebo daily. Throughout the study, participants will be monitored for any changes in their seizure frequency and any side effects they may experience.

The study aims to provide valuable information on the safety and effectiveness of XEN1101 as an additional treatment for people with focal onset seizures. By comparing the results between those taking XEN1101 and those taking the placebo, researchers hope to determine if XEN1101 can significantly reduce the number of seizures and improve the quality of life for individuals with this condition. The findings from this study could potentially lead to new treatment options for people living with focal onset seizures.